In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Eichenbaum about the cell and gene therapy pipeline ahead, what sustains a career in retina, and why lifting others up is just what you do.
Guidance includes building on existing science, reducing redundant testing, and accelerating treatments for rare and life-threatening diseases
Meeting founder and co-chair Arshad M. Khanani, MD, MA, FASRS, shares what attendees can expect during this year's program, opening the evening of June 12 and running through June 13 in Las Vegas, Nevada.
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.
Researchers report pseudophakic patients implanted with a peripheral vision IOL detected roadway hazards significantly faster than those receiving a standard monofocal lens.
Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.
Genetic testing transforms inherited eye disease care, but expert interpretation matters—learn why false negatives and new gene therapies reshape retina practice.
Researchers from Johnson & Johnson Vision and Aier Eye Hospital present 24-month prospective data showing that Chinese children wearing Abiliti™ 1-Day contact lenses experienced approximately half the axial elongation and myopia progression of a matched spectacle-wearing control group.
SOL-1 results show intravitreal axitinib hydrogel delivered superior vision maintenance and anatomic outcomes through 52 weeks.
Sharon Fekrat, MD, FACS, FASRS, reviews the science behind dopamine signaling in the retina and its potential role in the progression of age-related macular degeneration.
Dimitra Skondra, MD, PhD, FASRS, shares her perspective on the evolving treatment landscape for dry age-related macular degeneration and the key questions facing the field.
Carl D. Regillo, MD, FACS, reviews long-term efficacy and safety findings from the Port Delivery System clinical trial program.
Michael Singer, MD, discusses the role of steroids, biomarkers, and second-generation therapies in diabetic macular edema management.
Aixa Alarcon, PhD, and colleagues reported natural image analysis may better predict real-world visual performance of premium intraocular lenses than traditional single-frequency MTF testing, while also capturing the impact of dysphotopsias and residual astigmatism.
A modular AI system comprising six transformer models achieves near-expert concordance with an ASUWOG-aligned composite inflammation score
In this interview from the 2026 Retina World Congress, Katherine Talcott, MD underscores that retinal vein occlusions (RVOs) should prompt retina specialists to look beyond the eye and ensure patients are connected to primary care and cardiology. She highlights the importance of systemic risk factor management and interdisciplinary coordination as essential components of comprehensive RVO care.
Findings from an 856-patient analysis suggest that evaluating GA topography beyond foveal involvement may better capture patient-reported functional impairment.
The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.
The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.
Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.
At ARVO 2026, Michael Ip, MD, presented findings from a large-scale analysis of OCT biomarkers in patients with diabetic macular edema (DME), leveraging the robust DRCR Retina Network Protocol T dataset.
Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.
Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.
Ashkan Abbey, MD, reviews findings from the DAVIO2 and VERONA clinical trials for the bioerodible intravitreal insert.
Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.
Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.
Siegfried G. Priglinger, MD, FEBO, weighs in on the emerging rationale for gas-free, position-free macular hole surgery using an ILM flap.
Patricio G. Schlottmann, MD, examines why injection frequency drives treatment failure in wet AMD and the particular challenges facing patients in Latin America.
Victor M. Villegas, MD, discusses supraorbital vibration as an adjunct to topical anesthesia in a high-volume retina practice.
Posture, operating room setup, and small workflow adjustments can reduce cumulative neck and back strain over time.
